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Abstract Germinal centres (GCs) are T follicular helper cell (Tfh)-dependent structures that form
in response to vaccination, producing long-lived antibody secreting plasma cells and memory B
cells that protect against subsequent infection. With advancing age the GC and Tfh cell response
declines, resulting in impaired humoral immunity. We sought to discover what underpins the poor
Tfh cell response in ageing and whether it is possible to correct it. Here, we demonstrate that older
people and aged mice have impaired Tfh cell differentiation upon vaccination. This deficit is
preceded by poor activation of conventional dendritic cells type 2 (cDC2) due to reduced type 1
interferon signalling. Importantly, the Tfh and cDC2 cell response can be boosted in aged mice by
treatment with a TLR7 agonist. This demonstrates that age-associated defects in the cDC2 and Tfh
cell response are not irreversible and can be enhanced to improve vaccine responses in older
individuals.
Introduction
Successful T cell-dependent vaccines induce the formation of germinal centres (GCs) in secondary
lymphoid organs. The GC is a specialised microenvironment that produces long-lived humoral immu-
nity that can provide protection against subsequent infection (Vinuesa et al., 2016). Despite the suc-
cess of T cell-dependent vaccines to date in children and younger adults, vaccination is less effective
in older persons (Govaert et al., 1994). This has been proposed to be a result of a deterioration in
the magnitude and quality of the GC response (Aberle et al., 2013; Linterman, 2014;
Gustafson et al., 2018). Within the GC, antigen-specific GC B cells clonally expand and somatically
hypermutate the genes encoding their B cell receptor. This mutational process, coupled with subse-
quent affinity-based selection, results in the emergence of plasma cells and memory B cells that bind
antigen with improved affinity (Stebegg et al., 2018). The GC response is a highly collaborative pro-
cess that requires multiple cell types to interact at the right place and the right time: therefore,
defects in one or more of these cell types could underlie the poor GC response observed after vacci-
nation of older individuals. Both T cell-intrinsic defects and changes in the microenvironment have
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been implicated in the diminished GC response observed in older individuals (Yang et al., 1996;
Garcia and Miller, 2001; Eaton et al., 2004; Lefebvre et al., 2012; Linterman, 2014; Sage et al.,
2015; Gustafson et al., 2018; Nikolich-Zˇugich, 2018), but the precise cellular and molecular
changes that cause the age-dependent defects in the GC response remain unclear.
The GC response is absolutely dependent on T cell help. This is delivered by a specialised subset
of CD4+ T cells called T follicular helper (Tfh) cells, which provide survival and differentiation signals
to GC B cells (Vinuesa et al., 2016). Tfh cell differentiation from naı¨ve T cells is initiated by priming
by dendritic cells (DCs), which provide three signals to support Tfh cell formation
(Krishnaswamy et al., 2018): peptide-MHC-II, co-stimulation in the form of the CD28 ligands CD80
and CD86, and cytokines such as IL-6, IL-12 and IL-27 (Eddahri et al., 2009; Vinuesa et al., 2016;
Webb and Linterman, 2017). Several DC subtypes can initiate Tfh cell differentiation
(Chakarov and Fazilleau, 2014; Dahlgren et al., 2015; Yao et al., 2015; Levin et al., 2017;
Barbet et al., 2018), but migratory conventional type 2 dendritic cells (cDC2s) have been proposed
as the dominant Tfh cell-priming DC subset after vaccination (Krishnaswamy et al., 2017;
Krishnaswamy et al., 2018; Durand et al., 2019). Tfh precursor cells form after interactions with
cDC2s, and subsequent interactions with B cells support completion of Tfh cell differentiation and
localisation to the GC (Goenka et al., 2011; Baumjohann et al., 2013; Barnett et al., 2014). Once
within the GC, Tfh cells act as the gatekeepers of the B cell response by providing survival signals to
the highest-affinity GC B cells, thereby regulating which B cells are able to exit the GC as long-lived
plasma cells or memory B cells (Victora et al., 2010; Gitlin et al., 2014; Goenka et al., 2014;
Vinuesa et al., 2016). The selective help that Tfh cells provide is essential for the quality of the GC
response (Victora et al., 2010), and for preventing the emergence of autoreactive B cell clones from
the GC as long-lived plasma cells or memory B cells (Linterman et al., 2009). An impairment in the
formation of Tfh cells has been implicated in the defective GC response in aged mice
(Lefebvre et al., 2012; Sage et al., 2015). In this study we sought to identify the mechanism that
underlies poor Tfh cell formation in ageing, and to test whether it is possible to reverse the age-
dependent defects in Tfh cells.
Here, we report that the circulating counterparts of GC-Tfh cells are diminished in older persons
after seasonal influenza vaccination. This impairment in Tfh cell differentiation in humans could be
recapitulated in 2-year-old mice, which had fewer antigen-specific Tfh cells in the draining lymph
node (LN) after immunisation than younger adult mice. The defective Tfh cell response in aged mice
was linked with impaired T cell priming by cDC2s: after immunisation, fewer antigen-bearing cDC2s
were found in the draining LN of aged mice, and those that were present had reduced expression of
the co-stimulatory ligands CD80 and CD86. Transcriptional profiling of cDC2s from aged mice
revealed that they had a defective response to type I interferon (IFN-I) due to the reduced induction
of Ifnb1 after immunisation. Topical application of the TLR7 agonist imiquimod increased the num-
ber of antigen-bearing cDC2s, their expression of CD80 and CD86, and restored the formation of
antigen-specific Tfh cells in aged animals. This demonstrates that age-associated defects in Tfh cell
differentiation are not irreversible and that DCs are a rational target to boost responses to vaccina-
tion in older individuals.
Results
Circulating Tfh cells are reduced in older persons after vaccination
Circulating Tfh-like (cTfh) cells can be used in humans as a biomarker of concomitant GC reactions
after vaccination (Bentebibel et al., 2013). In our cohort of 18–36 year-old and 65–75 year-old indi-
viduals vaccinated with the 2014–2015 trivalent seasonal influenza vaccine (Figure 1A), there was a
five-fold reduction in the production of vaccine-specific antibodies in the serum of older persons
compared to younger participants (Figure 1B), consistent with previous reports (Govaert et al.,
1994; Goodwin et al., 2006; Sasaki et al., 2011; Nakaya et al., 2015). This diminished antibody
production with age was associated with reduced formation of cTfh cells that are transcriptionally
and clonally related to bona fide GC Tfh cells found in secondary lymphoid organs (Heit et al.,
2017; Brenna et al., 2020; Hill et al., 2019). Prior to vaccination, the frequency of CXCR5+PD-1+++
CD4+CD45RA- cTfh cells was similar in the two age groups (Figure 1C,D). Seven days after vaccina-
tion there were significantly fewer circulating Tfh-like cells in older persons compared to the younger
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individuals (Figure 1C,E), representing an impaired induction after vaccination when normalised to
an individual’s day 0 baseline (Figure 1F). Together, these data indicate that the GC-Tfh cell
response to vaccination is impaired in older persons.
Tfh cell and GC responses are impaired in ageing
A major limitation of human vaccination studies is the difficulty of sampling secondary lymphoid
organs after vaccination in large cohorts of people, and thus animal models are invaluable to under-
stand the underlying biology. After vaccination there is an increase in the number of Ki67+Bcl6+-
B220+ GC B cells in the draining inguinal LN in both younger 2–3 month-old adult and aged 22–24
month-old mice (Figure 2A–C, gating strategy in Figure 2—figure supplement 1). However, the
number of GC B cells was ten-fold lower in the aged mice ten days after immunisation, compared to
Figure 1. Poor induction of circulating Tfh (cTfh)-like cells in older persons upon influenza vaccination. (A) Vaccination and venepuncture schedule for
the seasonal influenza vaccination study, 18-36yo n = 16, 65-75yo n = 18. (B) Change in antibody titre of anti-A.Tex12 IgG, an influenza A
haemagglutinin (HA), from baseline 42 days after vaccination. Flow cytometric contour plots (C) and quantification of the frequency of CXCR5+PD-1+++
cells amongst CD45RA-CD4+CD3+ cells in the peripheral blood of healthy UK donors at days zero (D) and seven (E) relative to seasonal influenza
vaccination. (F) Fold change of cTfh-like cells in the peripheral blood seven days after vaccination over day zero (% CXCR5+PD-1+++CD45RA-CD4+CD3+
on day 7 divided by % CXCR5+PD-1+++CD45RA-CD4+CD3+ on day 0). Bar height corresponds to the median, and each circle represents one biological
replicate. P-values generated with a Mann-Whitney test. Data are from one seasonal influenza vaccination cohort from the northern hemisphere in
winter 2014–2015.
The online version of this article includes the following source data for figure 1:
Source data 1. Poor induction of circulating Tfh (cTfh)-like cells in older persons upon influenza vaccination.
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Figure 2. Germinal centre (GC) responses are impaired in aged mice. 2–3 month-old adult and 22–24 month-old aged C57BL/6 mice were
subcutaneously immunised with NP-1W1K (A-C, E-M) or NP-KLH (D) in Alum. Their draining inguinal lymph nodes (LNs) were analysed by flow
cytometry without immunisation (B, J, L), ten days after immunisation (A, C, E-G, H-I, K, M), or after 14 days by confocal imaging (D). (A-C)
Representative flow cytometric plots (A) and quantitation (B-C) of B220+Ki67+Bcl6+ GC B cells. (D) Confocal images of draining LNs from 2 to 3 month-
Figure 2 continued on next page
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younger adult mice (Figure 2C). This corresponded to a reduction in GC size (Figure 2D) and
reduced levels of antigen-specific antibodies in the serum of aged mice (Figure 2E–G), consistent
with previous reports that GC and antibody responses are reduced in magnitude in aged mice
(Kosco et al., 1989; Szakal et al., 1990; Yang et al., 1996; van Dijk-Ha¨rd et al., 1997;
Eaton et al., 2004; Linterman, 2014). This deficiency in the GC response was coupled with reduced
numbers of total CXCR5hiPD-1hiFoxp3-CD4+ Tfh cells prior to, and ten days after immunisation, as
well as significantly fewer antigen-specific Tfh cells, as assessed using 1W1K-loaded MHC-II tet-
ramers (Figure 2H–M; gating strategy in Figure 2—figure supplement 1; key resources are listed in
Supplementary file 1). This demonstrates that aged mice have impaired Tfh cell formation after
immunisation, which recapitulates the age-associated defect in Tfh cell formation observed in
humans (Figure 1).
T cell priming is impaired in aged mice
The age-associated deficit in Tfh cells upon immunisation could be due to T cell-intrinsic changes
with age, or due to the age of the microenvironment in which the T cells reside. After adoptive trans-
fer of either TCR-transgenic TCR7 or OTII CD4 T cells from 2 to 3 month-old mice into young adult
hosts, more than 80% of all transgenic CD4+ T cells had undergone one or more cell divisions after
immunisation (Figure 3A–D). In contrast, when cells from the same pool of TCR-transgenic T cells
were transferred into 22–24 month-old recipient mice, significantly fewer T cells had completed
more than one cell division (Figure 3A–D). In addition to defects in T cell priming, Tfh cell differenti-
ation of OTII CD4+ T cells isolated from 2 to 3 month-old mice was reduced three-fold ten days after
immunisation in aged mice compared to younger recipients (Figure 3E–F), which was associated
with reduced levels of antigen-specific antibodies in the serum of these mice (Figure 3—figure sup-
plement 1A–C). These observations indicate that the aged microenvironment causes impaired early
T cell activation and reduced Tfh cell development. These data prompt the hypothesis that the
reduced number of Tfh cells induced by immunisation in aged mice may be caused by defective T
cell priming.
Several DC subtypes, including LN-resident or migratory type 1 conventional DCs (cDC1s), cDC2s
and Langerhans cells, have been implicated in T cell priming (Chakarov and Fazilleau, 2014;
Woodruff et al., 2014; Yao et al., 2015; Levin et al., 2017; Barbet et al., 2018;
Krishnaswamy et al., 2018). Of these, the migratory cDC2 subset has been suggested as the domi-
nant Tfh cell-priming DC subset early after immunisation (Krishnaswamy et al., 2017;
Krishnaswamy et al., 2018; Durand et al., 2019). Consistent with these reports, after subcutaneous
immunisation with Ea-GFP the majority of GFP+ antigen-bearing cells in the draining LN were
CD11b+ cDC2s (Figure 3—figure supplement 1D–E; gating strategy from Guilliams et al. (2016).
These cells likely belong to the migratory cDC2s subset, as pertussis toxin treatment, which disrupts
G-protein coupled receptor-dependent cell migration, resulted in a reduced number of these anti-
gen-presenting cells in the draining LN (Figure 3—figure supplement 1F). One day after immunisa-
tion, aged mice had half the number of total and GFP+ CD11b+ cDC2s compared to younger
controls (Figure 3G–H). This was coupled with the reduced presentation of Ea peptide-MHC-II,
despite normal total MHC-II expression on the cell surface (Figure 3I–J, Figure 3—figure supple-
ment 1G). The expression of the costimulatory ligands CD86, CD80 and the receptor CD40 on the
Figure 2 continued
old and 22–24 month-old mice, taken 14 days after subcutaneous immunisation with NP-KLH. 10 mm LN sections were stained with anti-IgD (orange),
anti-CD3 (green), anti-Ki67 (blue) and anti-Foxp3 (pink) antibodies (n = 3–6). (E-G) Levels of NP-specific IgG1 antibodies in the serum of 2–3 month-old
and 22–24 month-old mice 10 days after immunisation with NP-1W1K in Alum as determined by ELISA. (E) Serum levels of NP20-specific IgG1
antibodies. (F) Serum levels of high-affinity NP7-specific IgG1 antibodies. (G) Ratio of NP20/NP7-specific IgG1 antibodies in the serum as a measure of
antibody affinity maturation. (H-M) Representative flow cytometric plots (H-I) and quantitation (J-M) of CXCR5hiPD-1hiFoxp3-CD4+ T follicular helper
(Tfh) cells (H, J-K) and antigen-specific 1W1K-I-Ab+ Tfh cells (I, L-M). Bar graphs show the results of one of two independent experiments (n = 8–12 per
group/experiment). Bar height corresponds to the median, and each circle represents one biological replicate. P-values were determined using Mann-
Whitney testing. The gating strategy is shown in Figure 2—figure supplement 1.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Germinal centre (GC) responses are impaired in aged mice.
Figure supplement 1. Gating strategy for GC B and Tfh cell populations.
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Figure 3. Activation of cDC2s and T cell priming are impaired in aged mice. (A–B) 1–5  106 CellTrace-labelled hen egg lysozyme (HEL)-specific TCR7
(CTV+TCRVb3+CD45.1+CD4+) cells or (C-D) 5  105 ovalbumin (OVA)-specific (CTV+TCRVa2+CD45.1+CD4+) OTII cells were adoptively transferred into
2–3 month-old and 22–24 month-old C57BL/6 recipients, which were subsequently immunised subcutaneously with HEL or OVA in Alum. Cell
proliferation of transferred cells was assessed in draining lymph nodes (LNs) by flow cytometry as defined by the serial dilution of CellTrace (CTV) three
days after immunisation (n = 3–6 per group/experiment). (A, C) Representative flow cytometric plot of CTV levels in CD45.1+CD4+ cells in 2–3 month-
old (white) and 22–24 month-old (grey) C57BL/6 recipients. The gate indicates cells that have undergone one or more divisions. (B, D) Percentage of
divided CTV+CD45.1+CD4+ cells in 2–3 month-old and 22–24 month-old C57BL/6 recipients. (E-F) 5  104 OVA-specific (CD45.1+TCRVa2+CD4+) OTII
cells were adoptively transferred into 2–3 month-old and 22–24 month-old C57BL/6 recipients, which were subsequently immunised subcutaneously
with NP-OVA in Alum in the hind flank to assess T follicular helper (Tfh) cell formation ten days after immunisation (n = 5–6 per group/experiment).
Representative flow cytometric plot (E) and quantitation (F) of CXCR5hiPD-1hi Tfh cells formed from CD45.1+CD4+ OTII cells in 2–3 month-old and 22–
24 month-old C57BL/6 recipients. (G-P) 2–3 month-old mice and 22–24 month-old were immunised subcutaneously with Ea-GFP in IFA. Antigen-
bearing GFP+ and antigen-presenting Y-Ae+dendritic cells (DCs) in draining LNs were analysed 22 hr after immunisation (n = 7–10 per group/
experiment). (G-H) Quantitation of total (G) and GFP+ (H) CD11b+ type 2 conventional DCs (cDC2s). (I-P) Representative histograms (I, K, M, O) and
quantitation of median fluorescence intensity (MFI) levels (J, L, N, P) of Y-Ae (I-J), CD86 (K-L), CD80 (M-N) and CD40 (O-P) on the surface of GFP+
CD11b+ cDC2s from 2 to 3 month-old and 22–24 month-old mice. Bar graphs show the results of one of at least two independent experiments. Bar
height corresponds to the median, and each circle represents one biological replicate. P-values were determined using the Mann-Whitney test.
Supporting data is shown in Figure 3—figure supplement 1.
Figure 3 continued on next page
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surface of GFP+ CD11b+ cDC2s was also diminished, indicating impaired activation of cDC2s with
age (Figure 3K–P). Taken together, these data suggest that defective T cell priming in draining LNs
of aged mice may be due to impaired antigen presentation and/or co-stimulation from the cDC2
subset.
The cDC2 response to IFN-I is reduced in aged mice
To determine whether impaired T cell priming in aged mice could be due to reduced antigen pre-
sentation by cDC2, we used mice that are haploinsufficient for MHC-II (H2+/- ), to mimic this age-
associated phenotype in younger mice. cDC2s from H2+/- mice present less peptide:MHC-II on their
surface 22 hr after immunisation (Figure 3—figure supplement 1H), but do not have an impaired
capacity to prime CD4+ T cells three days after immunisation (Figure 3—figure supplement 1I–J).
This indicates that a reduction in antigen-presentation alone does not phenocopy the defect in T cell
priming seen in aged mice, suggesting other age-dependent changes drive impaired T cell activa-
tion. CD80/CD86 co-stimulation is critical for both T cell priming and Tfh cell differentiation
(Platt et al., 2010; Wang et al., 2015b). By partially blocking these co-stimulatory ligands using a
CTLA4-Ig fusion protein in vivo, we observed a dose-dependent decrease in early T cell proliferation
(Figure 3—figure supplement 1K–L). Moreover, Wang et al. had previously demonstrated that
reducing the magnitude of CD28 signalling in vivo impairs Tfh cell differentiation (Wang et al.,
2015a). This implicates the age-associated reduction in the expression of CD80/CD86 on cDC2s as a
likely factor that contributes to impaired T cell priming and Tfh cell formation in aged mice.
To understand the molecular mechanism that underpins the age-associated cellular changes in
cDC2s, RNA sequencing was performed on sorted antigen-bearing cDC2s isolated from 2 to 3
month-old and 22–24 month-old mice 22 hr after immunisation with Ea-GFP (gating strategy shown
in Figure 3—figure supplement 1D). Principal component analysis (PCA) demonstrated distinct
clustering of samples with 47% of the variation in this dataset explained by age (Figure 4A). Gene
set enrichment analysis identified one pathway that was underrepresented in cDC2s from aged
mice: the cellular response to IFN-I (Figure 4B). This was driven by the reduced expression of the
majority of IFN-I inducible genes in aged mice compared to younger adults (Figure 4C). A reduction
in the IFN-I response in cDC2s was confirmed by quantitative Real-Time PCR (RT-qPCR) in an inde-
pendent cohort: expression of Ifit1 and Mx1, canonical IFN-I stimulated genes (ISGs), were reduced
in aged mice (Figure 4D–E). In unimmunised mice, the expression of Ifnb1 mRNA in the inguinal LN
was not detectable. Six hours after immunisation with Ea-GFP Ifnb1 is expressed in draining LNs,
but the induction of Ifnb1 expression was three-fold lower in 22–24 month-old aged mice compared
to 2–3 month-old adult mice (Figure 4F).
IFN-I responses are induced by IFNa and IFNb cytokines which bind the interferon alpha receptor
(IFNaR), a heterodimeric complex of IFNAR1 and IFNAR2 chains. Upon ligation of the IFNaR, the
Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2 transcription factors are phos-
phorylated and, in association with the interferon regulatory factor 9 (IRF9), move into the nucleus to
promote the expression of ISGs (Hoffmann et al., 2015). STAT1 phosphorylation levels and the
upregulation of the ISGs Ifit1 and Mx1 in cDC2s were intact in aged mice upon ex vivo treatment
with low levels of IFNa (Figure 4G–J). This indicates that aged cDC2s are capable of responding to
IFN-I and do not exhibit cell-intrinsic defects in IFN signalling. Consistent with this, cDC2s derived
from bone marrow (BM) stem cells from an aged, 23-month-old mouse transferred into an adult
recipient mouse, do not exhibit age-associated defects in number and activation after immunisation
when they develop and reside in the microenvironment of the younger host (Figure 4K–M).
Together, these data suggest that the poor activation of cDC2s in aged animals is not linked with
cell-intrinsic defects in their IFN-I response, but rather with impaired early induction of IFN-I in their
microenvironment.
Figure 3 continued
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Activation of cDC2s and T cell priming are impaired in aged mice.
Figure supplement 1. Migratory cDC2s are the main antigen-bearing cells in draining lymph nodes (LNs).
Figure supplement 1—source data 1. Migratory cDC2s are the main antigen-bearing cells in draining lymph nodes.
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Figure 4. Reduced type I interferon (IFN-I) signalling in cDC2s from aged mice. (A) Principal component analysis (PCA) of the 1000 genes with the
largest variance in sorted GFP+CD11b+ cDC2s cells from adult 2-month-old (blue) and aged 23-month-old (pink) mice (n = 6 per group). (B) Functional
categories significantly affected by age as determined by Gene Ontology Analysis using Seqmonk. From a publicly available list of gene sets
(Merico et al., 2010), significantly different gene ontology terms are shown (Kolmogorov-Smirnov test, p<0.05, average absolute z-score >1, multiple
Figure 4 continued on next page
Stebegg et al. eLife 2020;9:e52473. DOI: https://doi.org/10.7554/eLife.52473 8 of 30
Research article Immunology and Inflammation
Many different cell types can produce IFN-I upon infection or immunisation (Swiecki and
Colonna, 2011; Ali et al., 2019). To determine which cells express IFN-I in the draining LN after
immunisation we performed RT-qPCR for Ifnb1 in different FACS-sorted LN cell populations. This
revealed that plasmacytoid dendritic cells (pDCs) and CD64+F4/80+ macrophages express the high-
est levels of Ifnb1 16 hr after immunisation (Figure 4N). This indicates a potential link between age-
associated defects in cDC2s and the reduced production of Ifnb1 by pDCs and macrophages.
Previous reports have described an age-associated decline in IFN-I production by pDCs in both
humans and mice (Stout-Delgado et al., 2008; Panda et al., 2010; Sridharan et al., 2011;
Agrawal, 2013; Agrawal et al., 2017). In line with this, we found that age-associated defects in
cDC2 activation coincided with reduced numbers of pDCs in aged, 22–24 month-old mice compared
to adult controls upon immunisation (Figure 4O). To understand whether the reduction in pDCs was
due to the aged microenvironment, we irradiated aged mice and reconstituted these mice with BM
cells from 2 to 3 month-old animals. This revealed that the reduced number of pDCs in ageing is not
an intrinsic feature of aged stem cells, but is driven by age-associated changes in their microenviron-
ment (Figure 4P). In these chimeras GFP+ CD11b+cDC2 cell numbers and the expression of CD80/
86 on GFP+ CD11b+ cDC2 cells derived from young stem cells were reduced in aged BM recipients
(Figure 4Q–S). Together, this suggests that the poor activation of cDC2s in the LNs of aged animals
could be driven by reduced numbers of IFN-I-producing pDCs due to age-related changes in their
microenvironment.
Older persons have impaired IFN-I responses after vaccination
As observed in mice, the expression of IFN-I inducible genes is increased in the blood of people in
the first few days following vaccination (Nakaya et al., 2011; Athale et al., 2017). Using data from
Henn and colleagues (Henn et al., 2013), an early IFN-I gene signature was identified after seasonal
influenza vaccination in humans. This response peaks in the blood one day after vaccination
Figure 4 continued
testing correction). Bars are labelled with the number of genes in each set (inside) and the adjusted p-value (outside). (C) Average RPKM (read per
kilobase million) expression of IFN-I-responsive genes in GFP+ CD11b+ cDC2s as determined by RNA sequencing. RPKM expression values of the same
IFN-I stimulated gene in cDC2s from 2-month-old and 23-month-old mice are connected by lines. (D-E) 2–3 month-old and 22–24 month-old C57BL/6
mice were subcutaneously immunised with Ea-GFP in IFA. 22 hr later, Ifit1 (D) and Mx1 (E) mRNA levels were determined in sorted GFP+ CD11b+
cDC2s by RT-qPCR (n = 4–6 per group/experiment). (F) 2–3 month-old and 22–24 month-old C57BL/6 mice were subcutaneously immunised with Ea-
GFP in IFA. 6 hr later, Ifnb1 mRNA levels were determined in cells isolated from the draining lymph nodes (LN) by RT-qPCR (n = 5 per group/
experiment). (G-H) Representative flow cytometric plot (G) and quantitation (H) of STAT1 phosphorylation in CD11b+ cDC2s
(CD11b+CD11c+MHCII+CD172a+CD8-CD4-B220- cells) from 2 to 3 month-old and 22–24 month-old C57BL/6 mice upon ex vivo treatment of LN cells
with 50 U murine IFNa for 30 min, or no cytokine controls (n = 4–7 per group/experiment). (I-J) Ifit1 (I) and Mx1 (J) mRNA levels were determined in
sorted GFP+ CD11b+ cDC2s by RT-qPCR upon ex vivo treatment of LN cells with 50 U murine IFNa for 3 hr. Expression levels were normalised to age-
matched no cytokine controls (n = 5 per group/experiment). (K-M) Bone marrow (BM) cells from 3-month-old adult or 23-month-old aged mice were
transferred into 2-month-old irradiated CD45.1+ C57BL/6 recipient mice. 8 weeks later, these BM chimeras were immunised subcutaneously with Ea-
GFP in IFA. 22 hr later, DC populations were analysed by flow cytometry (n = 3–8 per group/experiment). (K) Quantitation of GFP+CD11b+ cDC2 cells
in the draining LNs of BM chimeras. (L-M) Quantitation of median fluorescence intensity (MFI) levels of CD86 (L) and CD80 (M) on the surface of
GFP+CD11b+ cDC2s in BM chimeras. (N) Ifnb1 expression in different cell populations FACS-sorted from the draining LNs of unimmunised adult mice
or mice immunised with EaGFP 16 hr earlier as determined by RT-qPCR. Cell populations were defined as follows: CD3+ T cells, CD19+ B cells,
macrophages (CD11c+CD64+F4/80+), pDC (CD3-CD19-B220+CD11c+PDCA1+), cDC1 (CD3-CD19-CD64-F4/80-MHC-II+CD11c+Xcr1+) and a population
including cDC2s and Langerhans (Lhs) cells (CD3-CD19-CD64-F4/80-MHC-II+CD11c+Xcr1-). (O) Flow cytometric quantitation of the number of
plasmacytoid DCs (pDCs; defined as B220+CD11c+CD11b-PDCA1+ cells) in the draining LNs of 2–3 month-old and 22–24 month-old C57BL/6 mice 22
hr after immunisation with Ea-GFP/IFA (n = 5–6 per group/experiment). (P-S) Bone marrow (BM) cells from 2-month-old CD45.1+ C57BL/6 SJL mice
were transferred into 2-month-old or 21-month-old irradiated C57BL/6 recipient mice. 8 weeks later, these BM chimeras were immunised
subcutaneously with Ea-GFP in IFA. 22 hr later, DC populations were analysed by flow cytometry (n = 2–5 per group/experiment). (P-Q) Quantitation of
CD45.1+ pDCs (P) and GFP+CD11b+ cDC2s (Q) in the draining LNs of BM chimeras. (R-S) Quantitation of median fluorescence intensity (MFI) levels of
CD86 (R) and CD80 (S) on the surface of CD45.1+GFP+CD11b+cDC2s in BM chimeras. Bar graphs show the pooled results from at least two
experiments except in (I-J), which show the results of one of two experimental repeats. Bar heights correspond to the median, and each circle
represents one biological replicate. In (N) bar heights correspond to the mean and error bars represent standard deviation. P-values were determined
using the Mann-Whitney test.
The online version of this article includes the following source data for figure 4:
Source data 1. Reduced type I interferon (IFN-I) signalling in cDC2s from aged mice.
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(Figure 5A). We further curated this list of IFN-I responsive genes to identify those that are robustly
induced in human blood one day after vaccination. Application of this curated IFN-I vaccination
Figure 5. Poor vaccine responses in older persons correlate with attenuated IFN-I signalling. (A) Time course of the expression of IFN-I-stimulated
genes in whole PBMC after influenza vaccination. Median expression of IFN-I-stimulated genes were calculated for each sample at each day and
normalised by the day 0 value. The mean and range for five individuals are shown. (B) Heatmap of expression values of a curated list of significant
probe sets for IFN-I-stimulated genes (ISGs) induced with a log2-fold change of >0.5 determined using the dataset in (A), and applied to days 0 and 1
in 18–36 year-old (18–36 yo; n = 19) or 65–86 year-old (65–85 yo; n = 39) individuals. (C) Principal component analysis (PCA) of the differentially
expressed ISGs from (B) with data from younger and older individuals plotted in blue and pink, respectively. Open circles represent data from day 0,
closed circles represent data from day 1 after vaccination, and boxplots represent the distribution of PC1 coordinates for each group. (D-F) The
distance from baseline to day 1 after vaccination on the PCA plot in (C) (‘IFN-I distance’) correlates with log2 fold-changes (day 28/day 0) of HAI titres
for A/Perth 2009 (D), B/Brisbane 2008 (E) and A/California 2009 (F). In (F-H), Spearman’s correlation coefficients (rho) and their p-values are shown and
younger and older individuals are plotted in blue or pink, respectively. Data are reanalysed from publicly available datasets (Franco et al., 2013;
Henn et al., 2013; Nakaya et al., 2015).
The online version of this article includes the following source data for figure 5:
Source data 1. Poor vaccine responses in older persons correlate with attenuated IFN-I signalling.
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signature to another dataset (Franco et al., 2013; Nakaya et al., 2015) showed that these genes
were induced in older persons after influenza vaccination, but to a lesser extent than in younger peo-
ple (Figure 5B), similar to our findings in aged mice (Figure 4). We performed PCA of the curated
vaccine-induced IFN-I genes to determine how much an individual’s IFN-I gene signature had
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Figure 6. Lack of IFN-I signalling in DCs impairs Tfh cell differentiation. (A–B) Quantitation of median fluorescence intensity (MFI) levels of CD80 and
CD86 on GFP+ CD11b+ cDC2s in mice treated with anti-IFNAR1 blocking or isotype control antibodies (n = 7 per group/experiment). (C-D)
Representative flow cytometric histograms (C) and quantitation (D) of divided CTV+CD45.1+CD4+, which had been transferred into Ifnar1-/- and Ifnar1+/
+ mice and immunised with ovalbumin (OVA) in Alum three days earlier (n = 6 per group/experiment). (E-H) Flow cytometric analysis (E, G) and
quantitation (F, H) of total (E-F) and 1W1K-I-Ab+ (G-H) CXCR5hiPD-1hiFoxp3-CD4+ T follicular helper (Tfh) cells isolated from Ifnar1fl/fl:Itgaxcre/+ or
Ifnar1fl/fl:Itgax+/+ control mice seven days after immunisation with NP-1W1K in Alum (n = 8–9 per group/experiment). Bar graphs show the results of one
of two experimental repeats. Bar height corresponds to the median, and each circle represents one biological replicate. P-values were determined
using the Mann-Whitney test. Supporting data is shown in Figure 6—figure supplement 1.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Lack of IFN-I signalling in DCs impairs Tfh cell differentiation.
Figure supplement 1. Lack of IFN-I signalling in DCs does not affect early antigen-specific antibody responses.
Figure supplement 1—source data 1. Lack of IFN-I signalling in DCs does not affect early antigen-specific antibody responses.
Stebegg et al. eLife 2020;9:e52473. DOI: https://doi.org/10.7554/eLife.52473 11 of 30
Research article Immunology and Inflammation
changed one day after vaccination compared to the baseline expression before vaccination (‘IFN-I
distance’) (Figure 5C). Day one samples from young people clustered distinctly from their pre-vacci-
nation samples, whereas older persons showed a diminished early IFN-I response, as shown by a
shorter IFN distance between day 0 and day 1 samples on the PCA plot. The IFN-I distance was
reduced by half in older compared to younger individuals (p<0.001). Increased IFN distances corre-
lated positively with an increased neutralising antibody titre 28 days after vaccination (Figure 5D–F),
demonstrating a correlation between the early IFN-I response and antibody titres upon vaccination
in people.
Lack of IFN-I signalling in DCs results in impaired Tfh cell formation
IFN-I signalling has previously been implicated in Tfh cell priming and protective immune responses
to vaccination in mice (Proietti et al., 2002; Cucak et al., 2009). Hence, we hypothesised that
reduced IFN-I signalling in cDC2s of aged mice could be linked with defective T cell priming. Block-
ade of IFN-I signalling prior to immunisation significantly reduced the expression of the co-stimula-
tory ligands CD80 and CD86 on cDC2s (Figure 6A–B), showing that a reduction of IFN-I signalling
can partly recapitulate the ageing cDC2 phenotype. Furthermore, absence of IFNaR in recipient
mice results in reduced T cell proliferation of adoptively transferred IFNaR-sufficient ovalbumin-spe-
cific OTII cells three days after immunisation (Figure 6C–D), similar to what had been observed in
aged mice (Figure 3C–D). To formally test the link between IFNaR signalling in DCs and Tfh cell for-
mation, Ifnar1fl/fI:Itgaxcre/+ mice, that lack IFNaR on CD11c+ cells such as DCs, and their IFNaR-suffi-
cient Ifnar1fl/fl:Itgax+/+ littermates were immunised with NP-1W1K in Alum. In the absence of
IFNAR1 on DCs, there was a defect in Tfh cell formation seven days after immunisation (Figure 6E–
H), without affecting serum levels of antigen-specific antibody at this early time-point (Figure 6—fig-
ure supplement 1A–C). This indicates that the lack of IFN-I signalling in DCs can mimic the age-
associated impairment of Tfh cell differentiation.
The TLR7 agonist imiquimod boosts cDC2s and tfh cell numbers
Our data demonstrate that cDC2 and Tfh cells from aged mice have impaired responses to vaccina-
tion. In an attempt to boost the response of these cell types upon vaccination we applied a cream
containing the TLR7-agonist imiquimod (Reiter et al., 1994; Moore et al., 2001) to the skin over
the immunisation sites (experimental set-up shown in Figure 7A). Imiquimod treatment is known to
induce IFN-I along with other cytokines and chemokines (Chen, 1988; Bottrel et al., 1999;
Sauder, 2003; Scho¨n and Scho¨n, 2007). Imiquimod treatment increased expression of the ISGs Ifit1
and Mx1 in antigen-bearing cDC2s from both 2–3- and 22–24 month-old mice compared to age-
matched no-imiquimod controls one day after immunisation (Figure 7B–C; Figure 7—figure supple-
ment 1A–B). This was associated with a two- to three-fold increase in the number of total and GFP+
CD11b+ cDC2s in draining LNs (Figure 7D–E; Figure 7—figure supplement 1C–D) and with a two-
fold increase in CD80 and CD86 on their surfaces (Figure 7F–G, Figure 7—figure supplement 1E–
F). Topical imiquimod treatment of Ifnar1-/- and Ifnar1+/+ mice revealed that the enhancing effects of
imiquimod on cDC2 numbers and activation were largely, but not completely, dependent on IFN-I
signalling (Figure 7H–J). This demonstrates that imiquimod treatment can boost the reduced IFN-I
response, and revert the numerical and co-stimulatory defects observed in cDC2s from aged mice.
Topical imiquimod treatment potently enhanced total and 1W1K-specific Tfh cell numbers in both
2–3- and 22–24 month-old mice seven days after immunisation (Figure 8A–F). This boost in Tfh cell
numbers was not dependent on intact IFN-I signalling in CD11c+ cells, as topical imiquimod treat-
ment enhanced total and 1W1K-specific Tfh cell numbers in Ifnar1fl/fl:Itgaxcre/+mice to the same
extent as in Ifnar1fl/fl:Itgax+/+ control mice seven days after immunisation (Figure 8G–H). That imiqui-
mod can enhance Tfh cells independently of IFN-I signalling in DCs indicates TLR7 stimulation has
multi-faceted roles in enhancing Tfh responses. Together, these results show that imiquimod treat-
ment can restore cDC2 activation and Tfh cell differentiation in aged mice. This was linked with a
doubling of GC B cell numbers in aged mice, but not in younger animals (Figure 8I–K). Imiquimod
treatment did not affect serum levels of antigen-specific antibodies at this early time-point when
most antibodies come from the extrafollicular plasmablast response (Figure 8—figure supplement
1A–C; MacLennan et al., 2003).
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Figure 7. Imiquimod rejuvenates cDC2s in aged mice by enhancing IFN-I signalling. (A) Schematic representation of the experimental set-up. (B-G) 22–
24 month-old mice were immunised subcutaneously with Ea-GFP in IFA. Half of the mice were topically treated with imiquimod cream over their
immunisation sites. 22 hr after immunisation with Ea-GFP in IFA, Ifit1 (B) and Mx1 (C) mRNA expression in sorted GFP+ CD11b+ cDC2s was analysed by
RT-qPCR. (D-E) Flow cytometric quantitation of total (D) and GFP+(E) CD11b+ cDC2 cells in the draining lymph nodes (LNs) of 22–24 month-old mice
with or without imiquimod treatment. (F-G) Quantitation of median fluorescence intensity (MFI) levels of CD86 (F) and CD80 (G) on the surface of GFP+
CD11b+ cDC2s in 23-month-old mice with or without imiquimod treatment. (H-J) 2 month old Ifnar1-/- and Ifnar1+/+ mice were immunised
subcutaneously with Ea-GFP in IFA and some of the mice were additionally treated with imiquimod cream over their immunisation sites. (H) 22 hr later
the number of GFP+ CD11b+ cDC2 cells in the draining lymph nodes (LNs) were quantified. (I-J) Quantitation of median fluorescence intensity (MFI)
levels of CD86 (I) and CD80 (J) on the surface of these GFP+ CD11b+ cDC2s. Bar graphs show the results of one of two independent experiments (B-G;
n = 6 per group/experiment) or the pooled results from two experiments (H-J; n = 3–11 per group). Bar height corresponds to the median, and each
circle represents one biological replicate. In (B-G) p-values were determined using the Mann-Whitney test. In (H-J) p-values were determined by
comparing each group to the ‘Ifnar1+/+ no imiquimod control’ group using the Kruskal Wallis test with Dunn’s multiple testing correction. Supporting
data is shown in Figure 7—figure supplement 1.
Figure 7 continued on next page
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Discussion
The humoral immune response to vaccination is diminished in older individuals, at least in part due
to defects in the GC response (Linterman, 2014; Gustafson et al., 2018). Here, we show that the
formation of Tfh cells is impaired in older persons and aged mice. In mice, we show topical applica-
tion of the TLR7 agonist imiquimod corrected the age-dependent defects in cDC2s and increased
the formation of Tfh and GC B cells in aged mice upon immunisation. This demonstrates that the
defect in the Tfh cell response in aged individuals is not irreversible, and can be corrected by exoge-
nous stimuli. Supporting our data, a clinical trial has demonstrated that topical imiquimod treatment
at the time of seasonal influenza vaccination enhances antibody responses to the vaccine in older
persons (Hung et al., 2014; Hung et al., 2016). This, together with the data presented here, dem-
onstrates that changing vaccination approaches is a rational strategy for improving vaccine efficacy
in older persons, a challenge of increasing importance with the rising population age world-wide.
Ageing has been reported to impair DC activation (Agrawal et al., 2007; Moretto et al., 2008),
the production of IFN-I cytokines by pDCs in both humans and mice (Stout-Delgado et al., 2008;
Panda et al., 2010; Sridharan et al., 2011; Agrawal, 2013; Agrawal et al., 2017), and the forma-
tion of Tfh cells (Garcia and Miller, 2001; Eaton et al., 2004; Lefebvre et al., 2012; Linter-
man, 2014; Gustafson et al., 2018; Nikolich-Zˇugich, 2018). In addition, Brahmakshatriya and
colleagues have demonstrated that transferring activated, in vitro BM-derived DCs into aged mice
can boost both the GC and Tfh cell response upon immunisation (Brahmakshatriya et al., 2017).
Our study demonstrates that age-associated defects in the early induction of IFN-I expression, prob-
ably by pDCs and macrophages, results in impaired expression of co-stimulatory molecules on
cDC2s. The impact of reduced IFN-I stimulation on cDC2s in aged mice can be multifactorial: in
DCs, IFN-Is promote the expression of co-stimulatory molecules and the cytokines IL-6, IL-27 and IL-
1b (Luft, 1998; Moretto et al., 2008; Cucak et al., 2009; Batten et al., 2010; Gringhuis et al.,
2014; Hassanzadeh-Kiabi et al., 2017). These molecules have been shown to enhance the expres-
sion of Bcl6, CXCR5 and ICOS by CD4+ T cells, thereby supporting differentiation towards the Tfh
cell phenotype (Cucak et al., 2009; Barbet et al., 2018). In particular, IL-6 production is reduced in
DCs from aged mice (Brahmakshatriya et al., 2017), which may act together with reduced co-stimu-
lation to contribute to poor Tfh cell priming in aged mice.
In an attempt to enhance cDC2 and Tfh cell responses upon vaccination, we applied a cream con-
taining the TLR7-agonist imiquimod, which has been shown to induce IFN-Is (Chen, 1988;
Bottrel et al., 1999; Sauder, 2003) to the skin of mice upon immunisation. Treatment with the TLR7
agonist imiquimod at the time of immunisation restored IFN-I signalling in cDC2s in aged mice,
increased their numbers in the draining lymph node and enhanced CD80/CD86 expression on their
surface. This demonstrated that IFN-I is an important signalling pathway to target to improve cDC2
functions in ageing. However, IFN-I signalling in cDC2s was not uniquely required for the imiqui-
mod-mediated increase in Tfh cell numbers in young mice. This suggests that other, non-IFN driven
effects of imiquimod, such as IL-6 production, can support Tfh cell formation (Scho¨n and Scho¨n,
2007; Walter et al., 2013). Alternatively, it may be that the induction of IFN-I signalling in cells
other than DCs, such as B cells or Tfh cells themselves is sufficient to promote Tfh cells (Le Bon
et al., 2006; Hervas-Stubbs, 2011; Nakayamada et al., 2014; Riteau et al., 2016; Li et al., 2018).
Together, this indicates that the TLR7 agonist imiquimod can boost cDC2 and Tfh cells using more
than one mechanism, reinforcing its potential as a vaccine adjuvant.
In our experiments, imiquimod treatment rescued the age-dependent defects in cDC2s and Tfh
cell differentiation but did not fully restore GC B cell numbers or early antigen-specific antibody
responses in aged mice to levels observed in younger adult mice. This could be due to additional
age-associated changes in other cell types involved in the GC and extrafollicular antibody response
(Linterman, 2014; Gustafson et al., 2018; Nikolich-Zˇugich, 2018). The most obvious hypothesis to
Figure 7 continued
The online version of this article includes the following source data and figure supplement(s) for figure 7:
Source data 1. Imiquimod rejuvenates cDC2s in aged mice by enhancing IFN-I signalling.
Figure supplement 1. Imiquimod induces IFN-I signalling and boosts cDC2 responses.
Figure supplement 1—source data 1. Imiquimod boosts Tfh cell differentiation in young mice.
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explain a poor GC response is that ageing results in cell-intrinsic defects in the GC B cells them-
selves. However, adoptive transfers of aged B cells into young hosts show that B cells from aged
mice are capable of forming GCs in a young environment, suggesting that a B cell-intrinsic defect is
not the cause of the poor GC response in aged mice (Yang et al., 1996). These data therefore impli-
cate B cell-extrinsic factors as additional contributors to the poor GC response in ageing. It is
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Figure 8. Imiquimod rejuvenates Tfh cell differentiation. 2–3 month-old and 22–24 month-old C57BL/6 mice (A-F, I-K) or 2 month old Ifnar1fl/fl:Itgaxcre/+
and Ifnar1fl/fl:Itgax+/+ littermate controls (G-H) were all subcutaneously immunised with NP-1W1K in Alum and then either topically treated with
imiquimod cream over their immunisation sites (‘Imiquimod’, Ifnar1fl/fl:Itgaxcre/+ and Ifnar1fl/fl:Itgax+/+ mice) or left untreated (‘Untreated’). Seven days
later, draining LN cells were analysed by flow cytometry. (A-F) Representative flow cytometric plots and quantitation of CXCR5hiPD-1hiCD4+ T follicular
helper (Tfh) cells (A-C) as well as antigen-specific 1W1K-I-Ab+ Tfh cells (D-F) in 22–24 month-old (A-B, D-E) and 2–3 month-old (C, F) mice. (G-H)
Quantitation of CXCR5hiPD-1hiCD4+ T follicular helper (Tfh) cells (G) as well as antigen-specific 1W1K-I-Ab+ Tfh cells (H) in two month old Ifnar1fl/fl:
Itgaxcre/+ and Ifnar1fl/fl:Itgax+/+ littermate controls seven days after immunisation with NP-1W1K in Alum and imiquimod treatment. (I-K) Representative
flow cytometric plots and quantitation of B220+Ki67+Bcl6+germinal centre (GC) B cells in 22–24 month-old (I-J) and 2–3 month-old (K) mice seven days
after immunisation with NP-1W1K in Alum with or without topical imiquimod treatment. Bar graphs show the results of one of three independent
experiments (G-H; n = 6–10 per group/experiment), or the pooled results of three independent experiments (A-F, I-K; n = 4–7 per group/experiment).
Bar height corresponds to the median, and each circle represents one biological replicate. P-values were determined using the Mann-Whitney test.
Supporting data is shown in Figure 8—figure supplement 1.
The online version of this article includes the following source data and figure supplement(s) for figure 8:
Source data 1. Imiquimod rejuvenates Tfh cell differentiation.
Figure supplement 1. Imiquimod treatment does not affect early antigen-specific antibody responses.
Figure supplement 1—source data 1. Imiquimod treatment does not affect early antigen-specific antibody responses.
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noteworthy that both T follicular regulatory (Tfr) cells and FDCs have been linked to the age-depen-
dent diminution of the GC response. The GC response is negatively regulated by Tfr cells
(Stebegg et al., 2018), that are reported to be increased in number in aged mice and this overrep-
resentation of Tfr cells may result in excessive suppression of the GC response in older animals
(Sage et al., 2015). There is also evidence that FDCs, stromal cells which are essential for the main-
tenance of the GC, are impaired in ageing (Wang et al., 2011). FDCs in aged mice form smaller net-
works and present fewer antigen-containing immune complexes on their surfaces after immunisation
(Aydar et al., 2003; Turner and Mabbott, 2017). This is likely to affect the ability of B cells to cap-
ture antigen for presentation to Tfh cells, which in turn provide B cell growth and differentiation
cues. This suggests that the age-associated defect in GC B cell expansion in mice is linked not only
with a defect in T cell priming but also with other factors such as reduced antigen retention on FDCs
and increased suppression by Tfr cells.
Several strategies are currently being used to enhance the response to vaccination in older per-
sons, including modifications of adjuvants (Frech et al., 2005) or administration of increased antigen
doses (Remarque et al., 1993). Hung and co-workers have shown that topical imiquimod treatment
at the time of vaccination enhances the antibody responses to influenza vaccination in both younger
and older persons (Hung et al., 2014; Hung et al., 2016). We have previously shown that the poor
gut GC response in aged mice can be boosted by replenishing the gut microbiome with that of a
younger animal (Stebegg et al., 2019). Together with the data presented here, this demonstrates
that age-related defects in the GC response are not irreversible and can be targeted therapeutically
to improve immune responses in older individuals. Because imiquimod can correct defective IFN-I
signalling and the associated cellular defects in cDC2s, and can also boost Tfh cell formation in aged
animals, this compound could play a key role in improving T-dependent vaccine responses, espe-
cially in the older members of our communities.
Materials and methods
Human seasonal influenza vaccination cohort
The main research objective of the human seasonal influenza vaccination study was to characterise
the cTfh and antibody response against seasonal influenza vaccination in humans in different age
groups. To that end, peripheral blood was tested from 34 healthy UK adults (18–75 years of age),
who were vaccinated with the trivalent influenza vaccine (2014/2015). Researchers remained blinded
to sample age throughout sample processing and data acquisition, and samples were selected at
random to be thawed and stained (2–10 samples per experiment). All human blood and tissue was
collected in accordance with the latest revision of the Declaration of Helsinki and the Guidelines for
Good Clinical Practice (ICH-GCP). The seasonal UK influenza vaccination cohort was collected with
UK local research ethics committee approval (REC reference 14/SC/1077), using the facilities of the
Cambridge Bioresource (REC reference 04/Q0108/44). Written informed consent was received from
all volunteers.
Peripheral blood was tested from 34 healthy UK adults (18–36 years of age n = 16, 65–75 years of
age n = 18) who were vaccinated with the trivalent influenza vaccine (northern hemisphere winter
2014–15). Blood samples were collected into silica-coated tubes (for serum) and EDTA-coated tubes
(for cells) on the day of vaccination (prior to administration of the vaccine), day 7 and day 42 after
vaccination, with approval from the UK local research ethics committee (REC reference 14/SC/1077),
and using the facilities of the Cambridge Bioresource (REC reference 04/Q0108/44). Peripheral
blood mononuclear cells (PBMCs) were isolated by density centrifugation on Histopaque-1077
(Sigma), and then cryopreserved in freezing medium (10% dimethyl sulfoxide, 90% FCS, both Sigma)
and kept in liquid nitrogen prior to analysis by flow cytometry. Cryopreserved PBMC were thawed
and rested in complete medium (RPMI-1640 with 10% FCS, 100 U/ml penicillin and 100 mg/ml strep-
tomycin, all Invitrogen) for 1 hr at 37˚C. Cells were resuspended at 4  107 per ml, then Fc receptors
were blocked using human IgG (Sigma), followed by staining with antibodies outlined in Table 1 and
analysis on a BD Aria Fusion cell sorter. A dump channel consisting of viability dye and antibodies to
CD14, CD16, and CD19 was used to exclude unwanted cell types from the analysis of circulating Tfh
cells (CD3+CD4+CD45RA-CXCR5+PD1+++), as previously described (Hill et al., 2019). The IgG
response was measured by Luminex using magnetic beads coated with full length recombinant
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haemagglutinin proteins from influenza strain A/Texas/50/2012 (A/Tex12), as previously reported
(Wang et al., 2015b).
Mouse housing and husbandry
C57BL/6, Ifnar1-/- (Skarnes et al., 2011), Ifnar1flox/flox (Le Bon et al., 2006),: Itgaxcre/+ (Caton et al.,
2007), OTII TCR-Tg (Barnden et al., 1998) and TCR7 TCR-Tg (Neighbors et al., 2006) mice were
bred and maintained in the Babraham Institute Biological Support Unit (BSU), where C57BL/6Babr
mice were also aged. No primary pathogens or additional agents listed in the FELASA recommenda-
tions (Ma¨hler et al., 2014) were detected during health monitoring surveys of the stock holding
rooms. Ambient temperature was ~19–21˚C and relative humidity 52%. Lighting was provided on a
12 hr light: 12 hr dark cycle including 15 min ‘dawn’ and ‘dusk’ periods of subdued lighting. After
weaning, mice were transferred to individually ventilated cages with 1–5 mice per cage. Mice were
fed CRM (P) VP diet (Special Diet Services) ad libitum and received seeds (e.g. sunflower, millet) at
the time of cage-cleaning as part of their environmental enrichment. All mouse experimentation was
approved by the Babraham Institute Animal Welfare and Ethical Review Body. Animal husbandry
and experimentation complied with existing European Union and United Kingdom Home Office leg-
islation and local standards (PPL: P4D4AF812). Young mice were 6–14 weeks old, and aged C57BL/6
mice 90–105 weeks old when experiments were started. All experimental mice were housed in the
same room. H2+/- mice (Madsen et al., 1999) and their wildtype littermates were maintained in spe-
cific pathogen–free facilities at the University of Leuven. All experiments were approved by the Uni-
versity of Leuven ethics committee.
Mice were randomly allocated into age- and sex-matched experimental groups by staff of the
Babraham Institute Experimental Support Unit or on the online mouse colony management system.
Blinding was not always possible due to visible phenotypic differences between aged and young
mice. For ageing experiments, a minimum of 5 mice per group were chosen based on previous
experience in the lab comparing GC responses in young and aged mice. Limited availability of aged
mice was a restricting factor in our study design. A minimum of 3 mice per group were chosen for
mechanistic studies, based on a literature-based assessment of the expected effect size between
study groups. Due to limited availability of aged female mice, all experiments with aged mice were
conducted with males. Other experiments were conducted with both male and female mice. All
experiments were repeated 2–4 times. Significant changes were reproducible between experimental
repeats. Some of the aged mice carried lymphomas or solid tumours which affected their immune
system, these mice were excluded from the analysis based on the following criteria: Mice with visible
lymphomas or large expansions of Ki67+ proliferating lymphocytes (as determined by Tukey’s outlier
test) were excluded. These criteria were in place prior to initiation of the study, as part of normal
practice for the use of ageing mice at the Babraham Institute.
Subcutaneous immunisations
Mice were immunised with either 1W1K-conjugate, OVA (ovalbumin), HEL (Hen Egg Lysozyme), NP-
OVA (4-hydroxy-3-nitrophenylacetyl-ovalbumin) or NP-KLH (4-hydroxy-3-nitrophenylacetyl-KLH) in
Table 1. Antibodies used for flow cytometry of human PBMC.
Antibody Company and clone Dilution
eFluor780 Viability dye eBioscience 1:5000
APC-eFluor780-coupled anti-human CD14 eBioscience (61D3) 1:50
APC-eFluor780-coupled anti-human CD16 eBioscience (eBioCB16) 1:50
APC-eFluor780-coupled anti-human CD19 eBioscience (HIB19) 1:50
BUV395-coupled anti-human CD3 BD (UCHT1) 1:100
PerCp-Cy5.5-coupled anti-human CD4 BD (RPA-T4) 1:50
BUV737-coupled anti-human CD45RA BD (HI100) 1:25
PE-Cy7-coupled anti-human PD1 eBioscience (eBioJ105) 1:25
BB515-coupled anti-human CXCR5 BD (RF8B2) 1:25
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Alum, or Ea-GFP in Incomplete Freund’s Adjuvant (IFA). IFA (#F5506), HEL (Lysozyme from chicken
egg white, #62970) and OVA (Albumin from chicken egg white; #A5503) were purchased from
Sigma-Aldrich, Imject Alum (#77161) was purchased from Thermo Fisher Scientific. NP-KLH (#N-
5060–25) and NP-OVA (#N-5051–100) were purchased from Biosearch Technologies. Ea-GFP fusion
protein was isolated in-house from XL-1 blue E. coli carrying the pTRCHis-Ea-GFP vector using a
protocol adapted from Rush and Brewer (2010). Briefly, E. coli carrying the pTRCHis-Ea-GFP vector
were plated from glycerol stock onto LB/ampicillin agar and incubated overnight at 37 ˚C. The next
day, a single colony was transferred into 5 ml LB and incubated at 37 ˚C while shaking. The next day,
these 5 ml were used to inoculate 1L LB. When the culture was growing in log phase, IPTG was
added to a final volume of 1 mM. The culture was left to shake overnight at 37 ˚C, then the bacteria
were pelleted at 5000 g for 15 min. After discarding the supernatant, the bacterial pellet was resus-
pended in 20 ml lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole at pH 8.0) by vortex-
ing and incubated on ice for 15 min in ice. After five repeated sonication steps on ice at 30 W for 60
s, the lysate was cleared by centrifugation at 10,000 g for 30 min. This step was repeated until all
Ea-GFP was released and the bacterial pellet did not appear green anymore. The clear, green lysate
was filtered first through a 0.45 mm syringe filter, then through a 0.22 mm syringe filter. Next, 200 ml
of lysate were mixed with 4 ml of Ni-NTA agarose (QIAGEN #30210) and incubated at 4 ˚C. After
one hour, the lysate/agarose mix was loaded onto 5 ml columns (QIAGEN #34964) and left to set.
The columns were then washed twice with 25 ml of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20
mM Imidazole at pH 8.0). The protein was eluted by four repeated additions of 2 ml elution buffer
(50 mM NaH2PO4, 300 mM NaCl, 250 mM Imidazole at pH 8.0) to the column. The eluate was dia-
lysed against PBS overnight in a D-Tube Dialyzer Mega 3.5 kDa tube (Millipore # 71743–4) at 4 ˚C.
On the next day, the eluate was concentrated using Centriprep centrifugal filters with an Ultracel
10K membrane (Millipore #4304) by centrifugation at 3000 g for 30 min. The concentrated protein
was collected, filtered through a 0.22 mm syringe filter and stored at  80 ˚C until use.
The 1W1K-conjugate was generated from NP-e-Aminocaproyl-OSu (Biosearch Technologies, #N-
1021–100), which was first conjugated to streptavidin (Sigma #S4762-10MG). The product was then
conjugated at a 1:6 molar ratio of NP-SA to 1W1K-biotin (custom-made by Cambridge Research Bio-
chemicals ‘biotin-GSGEA-W-GALANKA-V-DKA-acid’) for one hour at room temperature. Unbound
peptide was removed by dialysis using Centriprep centrifugal filters with an Ultracel10K membrane
(Sigma #4304). NP-1W1K was freshly conjugated for each experiment.
Purified 1W1K-conjugate, NP-KLH, HEL and OVA were first diluted in PBS, then the same volume
of Alum was added dropwise to the solution while shaking until a final concentration of 50 mg/ml
HEL, 500 mg/ml OVA, 500 mg/ml NP-OVA, 500 mg/ml NP-KLH or 330–500 mg/ml 1W1K-conjugate
was reached. After 30 min of vortexing, 100 ml of the emulsion were injected subcutaneously (s.c.)
into the hind flanks of recipient mice. 1 mg/ml Ea-GFP was emulsified in IFA by trituration through a
20 g needle. 200 ml of this emulsion were injected subcutaneously into the hind flanks of recipient
mice. Mice were euthanised at different time-points after immunisation, as indicated in the main text
or figure legends, when draining inguinal LNs were collected.
Where indicated, mice were treated with IFNAR1-blocking antibodies (BioXCell #BE0241),
CTLA4-Ig (Orencia Abatacept) or Aldara cream containing 5% imiquimod (MEDA Pharma) prior to,
or at the time of immunisation. IFNAR1 blocking was achieved by intraperitoneal injection of 0.75
mg of anti-IFNAR1 blocking antibody or the appropriate isotype control (BioXCell #BE0083) in 200
ml PBS 20 hr before immunisation with Ea-GFP. To block CD28 co-stimulation, 10–100 mg of Abata-
cept were injected intraperitoneally immediately prior to immunisations with HEL in Alum. For Aldara
treatment, mice were shaved on their backs 1–3 days before subcutaneous immunisations into their
hind flanks. Directly after immunisation, 50–125 mg of Aldara were applied topically to the shaved
backs of the anaesthetised animals. The cream was left to absorb for five minutes before the mice
were returned to their cages. Imiquimod-treated and untreated control mice were housed in sepa-
rate cages to avoid cross-contamination by grooming.
For pertussis toxin experiments, mice were subcutaneously injected into their hind flanks with 100
ml of 5 mg/ml pertussis toxin (Sigma #P7208) in PBS on days 0 and 1. On day 2, they received subcu-
taneous immunisations with 200 ml of 1 mg/ml Ea-GFP combined with 2.5 mg/ml pertussis toxin in
IFA. 22 hr later, mice were euthanised and their draining inguinal LNs were collected for flow cytom-
etry. Control mice were injected with 100 ml PBS on day 0 and 1 and were immunised with Ea-GFP
in IFA on day 2.
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Adoptive T cell transfers
To perform adoptive HEL- or OVA-specific T cell transfers, total lymphocytes were isolated from the
spleen and peripheral LNs (brachial, axial, superficial cervical, inguinal and mesenteric LNs) of TCR7
or OTII transgenic mice, respectively. These mice also expressed CD45.1+. All cells were stained
using the CellTrace Violet (CTV) Cell Proliferation Kit (Invitrogen #C34557; 1:1000 in PBS) for 15 min
at 37 ˚C, followed by two washes with PBS containing 2 %FBS at 1800 rpm for 5 min at 4 ˚C. The per-
centage of TCR-transgenic CD4+ CTV+ T cells was determined by flow cytometry, detecting TCR7 T
cells using anti-TCRVb3 antibodies and OTII T cells with anti-TCRVa2 antibodies. An equivalent of 1–
5  106 TCR7 T cells or 5  105 OTII T cells was transferred intravenously into C57BL/6, H2+/- or
Ifnar1-/- recipient mice in 100 ml 2% FBS/PBS. The mice were subsequently immunized subcutane-
ously into their hind flanks with 100 ml of 5–10 mg HEL or 50 mg OVA in Alum. An equivalent of
unstained 5  104 OTII T cells in 100 ml 2% FBS/PBS was transferred intravenously into adult and
aged C57BL/6 mice for the assessment of Tfh cell differentiation on day 10 after immunisation with
50 mg NP-OVA in Alum. Where indicated, mice were pre-treated intraperitoneally with 1, 50 or 100
mg CTLA4-Ig (Orencia Abatacept) in 100 ml PBS at the time of T cell transfer to block CD86 and
CD80 co-stimulation. After three days, the inguinal LNs of each recipient mouse were harvested and
pooled. They were mashed through 70 mm filters to obtain single cells which were then stained for
flow cytometry. The antibodies used are listed in Table 2.
Bone marrow chimeras
Recipient mice (2-month-old CD45.1+ C57BL/6 SJL or 2-month-old and 21-month-old C57BL/6 mice)
were irradiated with 800–1000 rad in two doses and reconstituted via intravenous injection with 2–
4  106 BM cells isolated from donor mice (2–3 month-old CD45.1+ C57BL/6 SJL, 3-month-old or
23-month-old C57BL/6 mice). BM chimeras were administered neomycin in their drinking water for
the first four weeks after BM transfers and were used for experiments eight weeks after successful
reconstitution.
Flow cytometry
For T and B cell stains a single cell suspension from inguinal LNs was generated by pressing the tis-
sues through a 70 mm mesh in 2% FBS in PBS. Cell numbers and viability were determined using a
CASY TT Cell Counter (Roche). 1–3  106 cells were transferred to FACS tubes or 96-well plates for
subsequent antibody staining. To stain for 1W1K-specific CD4 T cells, cell suspensions were first pre-
treated with Dasatinib (BioVision #1568–100, 1:20,000 in DMEM (Dulbecco’s modified eagle
medium, Gibco #41965–039) containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin)
for 10 min at 37 ˚C. Then, a PE-conjugated MHC class II tetramer containing the 1W1K peptide
(obtained through the NIH Tetramer Core Facility; PE-coupled ‘I-A(b) EAWGALANKAVDKA’) was
added to each sample at a final concentration of 1:100 and incubated for 2 hr at room temperature.
Cells were stained with LIVE/DEAD Fixable Blue Dead Cell Stain (Invitrogen #L23105; diluted 1:1000
in PBS) and incubated with FcR block for 15 min (anti-mouse CD16/32; eBioscience #14-0161-82;
diluted 1:50 in 2% FBS in PBS). Surface antibody stains were performed for 1 hr at 4 ˚C in 100 ml Bril-
liant Stain Buffer (BD Biosciences #563794). For intranuclear staining, cells were fixed with the eBio-
science Foxp3/Transcription Factor Staining Buffer (#00-5323-00). Antibody staining with anti-Foxp3,
anti-Ki67 and anti-Bcl6 antibodies was performed for 1–2 hr at 4 ˚C in 1  Permeabilization buffer
(eBioscience #00-8333-56). Samples were acquired on an LSRFortessa (BD Biosciences) with stained
UltraComp eBeads Compensation Beads (Invitrogen #01-2222-41) as compensation controls. Flow
cytometry data were analysed using FlowJo v10 software (Tree Star). The antibodies used are listed
in Table 2.
For DC analysis, inguinal LNs were harvested and incubated with 10 mg/ml Collagenase D (Roche
#11088866001) in plain RPMI medium (Gibco #11875093) for 15–30 min at 37 ˚C, followed by gentle
pipetting to disrupt the tissue. Cells were washed with PBS containing 2% FBS, before cell numbers
were determined using a CASY TT Cell Counter (Roche). After a wash in PBS, isolated cells were
stained with LIVE/DEAD Fixable Blue Dead Cell Stain (Invitrogen #L23105; diluted 1:1000 in PBS) on
ice for 10 min. After a second wash, they were blocked with FcR block (anti-mouse CD16/32; eBio-
science #14-0161-82; diluted 1:50 in 2% FBS in PBS) for 10–15 min at 4 ˚C. Surface antibody stains
were performed for 45–60 min at 4 ˚C in Brilliant Stain Buffer (BD Biosciences #563794). Samples
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were acquired on a LSRFortessa 5 and sorted with a BD FACSAria (both BD Biosciences). Flow data
were analysed using FlowJo v10 software (Tree Star). The antibodies used are listed in Table 2.
To stain for pSTAT1,~2106 cells isolated from the inguinal LNs of naı¨ve mice were seeded into
sterile round-bottom 96-well plates in 200 ml complete RPMI (RPMI medium (Gibco #11875093) con-
taining 10% FBS (Sigma #F9665), 100 U/ml penicillin/streptomycin (Thermo Fisher Scientific #15140–
122) and 55 mM 2-mercaptoethanol (Thermo Fisher Scientific #21985023)). After a 45 min resting
Table 2. Antibodies and conjugated probes used for flow cytometry and FACS of mouse tissues.
Antibody Supplier (Clone) Dilution
PE/PE-Cy7-coupled anti-mouse Bcl6 BD Biosciences (K112-91) 1:100
PE-Cy7-coupled anti-mouse CD95 BD Biosciences (Jo2) 1:200
BV605-coupled anti-mouse IgG1 BD Biosciences (A85-1) 1:100
PE-Cy7/BUV395-coupled anti-mouse CD3 BD Biosciences (145–2 C11) 1:300
PE-Cy7/BUV395-coupled anti-mouse CD19 BD Biosciences (1D3) 1:200-1:300
PE-Cy7/BUV395-coupled anti-mouse B220 BD Biosciences (RA3-6B2) 1:300
BUV395-coupled anti-mouse CD8a BD Biosciences (53–6.7) 1:200
AF647-coupled anti-mouse CD64 BD Biosciences (X54-5/71) 1:200
PE-Cf594-coupled anti-mouse CD11b BD Biosciences (M1/70) 1:200
BV786-coupled anti-mouse CD103 BD Biosciences (M290) 1:200
PE/BV510-coupled anti-mouse CD86 BD Biosciences (GL1) 1:300
APC-AF780-coupled anti-mouse PD1 eBioscience (J43) 1:200
APC/Foxp3-coupled anti-mouse Foxp3 eBioscience (FJK-16S) 1:100-1:200
AF488/AF700-coupled anti-mouse Ki67 eBioscience (SolA15) 1:100
Biotin-coupled anti-mouse Gr1 eBioscience (RB6-8C5) 1:200
eF450-coupled anti-mouse CD38 eBioscience (90) 1:400
PerCp-Cy5.5-coupled anti-mouse CD172a eBioscience (P84) 1:200
eF450-coupled anti-mouse CD24 eBioscience (M1/69) 1:500
APC/APC-AF870-coupled anti-mouse CD11c eBioscience (N418) 1:200
PE-Cy5/APC-coupled anti-mouse CD80 eBioscience (16-10A1) 1:300
PerCp-Cy5.5-coupled anti-mouse CD45.2 eBioscience (104) 1:200
AF700-coupled anti-mouse MHC-II eBioscience (M5/114.12.2) 1:400
BV421-coupled anti-mouse CXCR5 Biolegend (L138D7) 1:100
V500/PE/BV605-coupled anti-mouse CD4 Biolegend (RM4-5) 1:400-1:800
BV510/BV785-coupled anti-mouse B220 Biolegend (RA3-6B2) 1:200-1:400
PerCp-Cy5.5-coupled anti-mouse CD44 Biolegend (IM7) 1:200
AF488-coupled anti-mouse GL7 Biolegend (GL7) 1:100
BV605/PE-coupled anti-mouse F4/80 Biolegend (BM8) 1:200
BV650-coupled anti-mouse XCR1 Biolegend (ZET) 1:200
PE-Cy7-coupled anti-mouse CD40 Biolegend (3/23) 1:300
AF700-coupled anti-mouse CD45.1 Biolegend (A20) 1:200
PerCp-Cy5.5-coupled anti-mouse PDCA-1 Biolegend (927) 1:100
PE-coupled anti-mouse TCR Vb3 BD Biosciences (KJ25) 1:100
APC-coupled anti-mouse TCR Va2 eBioscience (B20.1) 1:100
APC/PE-Cy7/BV510-coupled Streptavidin StrepavidinStreptavidin Biolegend, eBioscience 1:600
Biotin-coupled anti-mouse Ea 52–68 peptide eBioscience (eBioY-Ae) 1:200
PE-coupled 1W1K-IAb tetramer NIH Tetramer core facility 1:100
PE-coupled anti-mouse pSTAT1 BD Biosciences Phosflow (pY701) 1:10
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period, they were treated with 50 U/well recombinant murine IFNa (PBL assay science #12105–1) for
30 min and simultaneously stained with fluorochrome-coupled anti-mouse CD8a, B220 and CD11b
antibodies. The cells were then washed and fixed with Cytofix (BD Biosciences #554655) for 30 min,
followed by a 30 min fixation and permeabilisation step in ice-cold 90% methanol. After three
washes in PBS, the cells were stained with anti-mouse pSTAT1 antibodies as well as anti-mouse
CD4, CD11c, MHCII, CD172a antibodies for one hour. Samples were acquired on a LSRFortessa 5
and the flow data were analysed using FlowJo v10 software (Tree Star). The antibodies used are
listed in Table 2.
Fluorescence-activated cell sorting (FACS)
For RT-qPCR of GFP+ CD11b+ cDC2, cells from total draining LNs were isolated and stained as
described above. 800–4000 GFP+ CD11b+ cDC2 were sorted into PCR tubes containing 20 ml of RLT
lysis buffer supplied with the RNeasy Micro Kit (Qiagen #74004) using a BD FACSAria or FACS Aria
Fusion. For RNA sequencing, we sorted 800 cells into PCR tubes containing 8.5 ml of 1  lysis buffer
provided with the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Clontech # 634890).
To determine the IFN-I responsiveness of cDC2s ex vivo,~2106 cells isolated from the inguinal
LNs of naı¨ve mice were seeded into sterile round-bottom 96-well plates in 200 ml complete RPMI.
After a 15 min resting period, they were treated with 50 U/well recombinant murine IFNa (PBL assay
science #12105–1) for 3 hr and then stained and sorted CD11b+ cDC2s as described above.
To investigate Ifnb1 expression of different LN cell subsets we sorted different cell populations
based on a gating strategy proposed by Guilliams et al. (2016): T cells (CD3+), B cells (CD19+), mac-
rophages (CD11c+F4/80+CD64+), pDCs (CD3-CD19-CD11c+B220+PDCA1+), cDC1s (CD3-CD19-F4/
80-CD64-MHC-II+CD11c+Xcr1+) and a population containing both cDC2s and Langerhans cells
(CD3-CD19-F4/80-CD64-MHC-II+CD11c+Xcr1-) from the pooled draining LNs of 4–5 mice 16 hr after
immunisation with Ea-GFP in IFA. To sort DCs and macrophages, LN were digested as described
above and Miltenyi’s pan dendritic cell isolation kit (#130-100-875), LS columns (Miltenyi #130-042-
401) and a MidiMACS separator (Miltenyi) were used to magnetically enrichment for CD11c+ cells,
by following the manufacturer’s instructions. The DC-enriched cell fraction was stained as described
above. All cell types were sorted into separate 5 ml tubes containing 300 ml FBS using a BD FACSA-
ria Fusion. RNA for RT-qPCR was isolated from cell pellets using Qiagen’s RNeasy Mini or Micro Kit
(#74104 and #74004).
Confocal imaging of germinal centres
Draining inguinal LNs were fixed in periodate-lysine-paraformaldehyde (PLP) containing 1% (v/v) PFA
(Sigma #P6148), 0.075 M L-Lysine (Sigma #L5501), 0.37 M Na3PO4 (pH 7.4) (Sigma #342483) and
0.01 M NaIO4 (Sigma #210048), for 4 hr at 4 ˚C. After fixation, the samples were dehydrated in 30%
sucrose (Sigma #S0389) overnight, embedded in Optimum Cutting Temperature (OCT) medium
(VWR #25608–930) on dry ice and stored at  80 ˚C. The frozen tissues were cut into 10 mm sections
using a cryostat (Leica Biosystems) at  20 ˚C and again stored at  80˚C. For antibody stains, the
slides were first air-dried and then hydrated in 0.5% Tween 20 in PBS (PBS-T). Slides were blocked in
200 ml blocking buffer (PBS containing 2% BSA and 10% goat serum), then permeabilised with 200
ml PBS containing 2% Triton X (Sigma #X100). After three wash steps in PBS-T, the slides were incu-
bated with 200 ml of a primary antibody mix in PBS-T containing 1% BSA at 4 ˚C overnight. Sections
were stained with eF450-conjugated rat anti-mouse Foxp3 (clone FJK16S, Thermo Fisher Scientific;
1:50), hamster anti-mouse CD3e (clone 500A2, Thermo Fisher Scientific; 1:200), rabbit anti-mouse
Ki67 (#15580, Abcam; 1:100) and AF647-conjugated rat anti-mouse IgD (clone 11–26 c.2a, Biole-
gend; 1:100). The next day, the slides were washed in PBS-T three times, then they were incubated
with secondary antibodies in 200 ml PBS-T containing 2% goat serum for 2 hr at room temperature.
The secondary antibodies used were AF568-conjugated goat anti-hamster IgG (#A-21112, Life Tech-
nologies; 1:500) and AF488-conjugated goat anti-rabbit (#150077, Abcam; 1:400). Hydromount
mounting medium (National diagnostics #HS-106) was used to mount slides and coverslips were
gently placed on top of the slides. Slides were dried overnight for the mounting medium to set.
Images were acquired using a Zeiss 780 microscope using 10, 20  and 40  objectives. Image
analysis was performed using ImageJ.
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RNA isolation and quantitative Real-Time PCR (RT-qPCR)
RNA isolation from ex vivo isolated cells was performed using Qiagen’s RNeasy Mini or Micro Kit
(#74104 and #74004) following the manufacturer’s instructions. Homogenisation of the samples was
achieved by vortexing for 1 min or by using QIAshredders (Qiagen #79654). RNA concentrations
obtained from the RNA isolation were measured using the NanoDrop system (Thermo Fisher
Scientific).
The TaqMan Gene Expression Assay (Thermo Fisher Scientific #4331182) for Ifnb1
(Mm00439552_s1) detects genomic DNA, so RNA samples were treated with the Turbo DNA-free
kit (Thermo Fisher Scientific #AM1907) according to the manufacturer’s protocol to remove any con-
taminating genomic DNA for RT-qPCR. cDNA was generated from pre-treated RNA samples using
the Quantitect reverse transcription kit (Qiagen #205311) and RT-qPCR for Ifnb1, Mx1
(Mm00487796_m1) and Ifit1 (Mm00515153_m1) was performed using the Platinum Quantitative PCR
SuperMix-UDG (Thermo Fisher Scientific #11730025). In some cases, RT-qPCR using TaqMan Gene
Expression Assays for Mx1 and Ifit1, which do not detect genomic DNA, was performed directly on
RNA using Thermo Fisher Scientific’s TaqMan RNA-to-CT 1-Step Kit (#4392656) following the manu-
facturer’s protocol. All RT-qPCR reactions were assembled in PCR 96-well (Bio-Rad #MLL9601) or
384-well plates (Bio-Rad #HSP3805), adding 2 ml of template RNA or cDNA (10–50 ng per reaction)
to 8 ml of a master mix containing the appropriate TaqMan Gene Expression Assay. Expression levels
were normalised to Hprt (Mm03024075_m1), which was found to be stably expressed under all
experimental conditions.
All samples were run in duplicates or triplicates on a BioRad CFX96 or CFX384 Real-Time System.
The 2-DDCt-method was applied for relative quantification of mRNA levels. Samples from young mice
were used as calibrators. As above, Cq values were exported from the CFX Manager software (Bio-
rad).
Enzyme-linked immunosorbent assay (ELISA)
ELISA plates (Thermo Fisher Scientific 96F Maxisorp #456537) were coated overnight at 4 ˚C with 10
mg/ml NP20-BSA (Biosearch Technologies #N-5050H-100) or 2.5 mg/ml NP7-BSA (Biosearch Technol-
ogies #N-5050L-100) in PBS. The next day, plates were washed 4 times in wash buffer containing
0.05% Tween 20 in PBS and blocked with 1% BSA in PBS for 1 hr at room temperature. After an
additional wash step, sera were loaded onto the plates. The starting dilution for sera was 1:50–200
in 1% BSA in PBS. This initial dilution was titrated down the plate at a 1:3 or 1:4 ratio. The plates
were incubated for 2–3 hr at room temperature and after another wash step 50 ml of polyclonal goat
anti-mouse IgG1 HRP-conjugated antibodies (Abcam #ab97240; 1:10,000 in PBS) were added for 2
hr at room temperature. The plates were developed with 100 ml/well TMB (Biolegend #421101) for
up to 20 min, when the reaction was stopped with 50 ml/well 0.5M H2SO4. A PHERAstar FS micro-
plate reader (BMG Labtech) was used to measure absorption at 450 nm. Absorbance values from
serially diluted samples were plotted and values which fell into the linear range of the curve were
selected to calculate endpoint titres.
RNA sequencing
Samples for RNA sequencing were obtained from 16 mice in one FACS sort. cDNA was prepared
from sorted cells using the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Clontech #
634890) on the day of the sort following the manufacturer’s protocol. 400 pg of cDNA per sample
were used as input for the preparation of sequencing libraries with the Illumina Nextera XT kit (#FC-
131–1096) following the manufacturer’s instructions. The quality of the cDNA and libraries was
assessed using Agilent Bioanalyser High Sensitivity DNA Chips (#5067–4626), and Qubit dsDNA
High Sensitivity Assay Kit (Invitrogen #Q32854) on a Qubit 4 Fluorometer (Invitrogen). Six samples
from young mice and six samples from aged mice passed all quality controls, were pooled onto two
HiSeq sequencing lanes and sequenced as 100 bp single-end reads. RNA sequencing analysis was
performed using the SeqMonk software package (Babraham Institute, https://www.bioinformatics.
babraham.ac.uk/projects/seqmonk/) after trimming (Trim Galore v0.4.2) and alignment of reads to
the reference mouse genome GRCm38 using HISAT2 (Kim et al., 2015). Reads were quantitated
over exons and library size was standardized to 1 million reads, and then read counts were log2
transformed. Differentially expressed genes were determined by DESeq2 analysis using raw counts
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(adjusted p-value cut-off p0.05) (Love et al., 2014). Principal component analysis was performed
using 1000 genes with the largest variances, after normalisation for batch effects with RUVSeq
(Risso et al., 2014).
To test for the differential expression of functionally related gene sets, a publicly available list of
gene sets (Mouse_GO_AllPathways_with_GO_iea_December_24_2014_symbol.gmt.txt of Bader Lab
EM_Genesets Merico et al., 2010) was filtered for categories containing less than 20 or more than
500 genes. Resulting gene sets were tested for differential expression between young and aged
samples using Seqmonk Subgroup Statistics (Kolmogorov-Smirnov test, p<0.05, average absolute
z-score >1, multiple testing correction). Genes in the Responsiveness to IFN-I pathway: Stat1, Aim2,
Pyhin1, Ifi204, Ifi203, Ifi202b, Ifi205, Gbp3, Gbp2, Ifnb1, Gbp6, Htra2, Ndufa13, Trex1, Pnpt1,
Tgtp1, Irf1, Igtp, Ddx41, Tmem173, Gm4951, Iigp1, Ifit3, Ifit1.
Publicly available datasets
PBMC RNA-Seq data from GSE45735 were used to assess an individual’s IFN response over time
(Henn et al., 2013). Corresponding fastq files were obtained from SRA using the sratoolkit (https://
www.ncbi.nlm.nih.gov/sra/) and aligned to GRCh38 using HISAT2 (Kim et al., 2015). Counting, at
gene level, was performed with Rsubread (Liao et al., 2019). Variance stabilised normalisation (VSN,
as implemented in DESeq2 Huber et al., 2002; Love et al., 2014) was applied to the counts to give
an expression value per gene. To analyse the IFN-I response in these datasets we used the ‘HALL-
MARKS’ IFN alpha response, which is a gene set curated by MSigDB at the Broad Institute based on
experimentally derived expression data (Subramanian et al., 2005; Liberzon et al., 2015), and
which we have used previously to identify and validate a role for IFN-I in the formation of ectopic
lymphoid structures (Denton et al., 2019).
Microarray data from GSE74813 (Franco et al., 2013; Nakaya et al., 2015) were re-analysed as
follows: Raw. CEL files were downloaded from GEO with the corresponding annotation data. CEL
files were read into R via readAffy (Gautier et al., 2004) and were normalised using VSN
(Huber et al., 2002). The dataset was then subsetted to select only individuals with paired day 0
and day 1 samples. Genes were selected as described in the results section. Antibody titres were
made available upon request (Nakaya et al., 2015).
Statistics
All mouse experiments were performed twice or more with 3–10 mice per group. Differences
between experimental groups were assessed using the non-parametric Mann–Whitney or Kruskal-
Wallis test combined with Dunn’s multiple testing correction within the Prism v6 and v7 software
(GraphPad). Outliers as determined by Tukey’s outlier test within the Prism software were excluded
from the analysis. Test Rank correlations were determined using Spearman’s correlation coefficients
(rho). p-values0.05 were considered statistically significant. For RNA sequencing analysis, sequenc-
ing reads were quantitated over exons and library size was standardized to 1 million reads, and then
read counts were log2 transformed. Differentially expressed genes were determined by DESeq2
analysis using raw counts (adjusted p-value cut-off p0.05).
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